paul young cpa, cga, profile picture
Uploaded bypaul young cpa, cga
PPTX, PDF460 views

COVID19| What's next

The document discusses the development of COVID-19 vaccines by various companies, highlighting key players like CanSino Biologics, Novavax, and CureVac, along with their financial performance and vaccine platforms. It also touches on testing strategies, the global market for testing, antibody treatments, and mitigation strategies for pandemic responses. The content emphasizes the collaboration between governmental funding and private initiatives in accelerating vaccine development and addressing public health needs.

Download to read offline
RACE TO COVID19 VACCINE AND TESTING PAUL YOUNG CPA CGA JULY 15, 2020
PAUL YOUNG CPA CGA – BIO September 9, 2014 • CPA, CGA • Financial Solutions • SME – Risk Management • SME – Emerging Technology • SME – Business Process Change • SME – Close, Consolidate and Reporting • SME – Public Policy • SME – Financial Solutions • SME – Supply Chain Management Contact – Paul.Young@ca.ibm.com
INTRODUCTION This presentation takes a look at what is happening with the COVID19 vaccine development.
AGENDA  Pharma and Vaccines development  Key Companies  CANSINO BIOLOGICS INC.(6185)  Symvivio Corporation  Novovax  CureVac  Generex  Vaxart  Medicago  Takis  Altimmune  Testing  Testing Kits  Global Market / Testing  Effective Treatments  Antibodies  Mitigation  Summary
MAJOR PLAYERS / VACCINES DEVELOPMENT
FINANCIAL PERFORMANCE KEY COMPANIES
CANSINO BIOLOGICS INC.(6185)  100% of the revenue is in China - https://www.marketscreener.com/CANSINO-BIOLOGICS-INC- 59318312/company/  The chair is McGill graduate. https://www.marketscreener.com/business- leaders/Xue-Feng-Yu-0DD2L9-E/biography/ Trudeau attended McGill and McGill has high Chinese enrolment - https://www.mcgill.ca/international/channels/news/mcgill-news-china- tops-international-enrolment-mcgill-first-time-291377  J&J and Casino have similar vaccine - https://www.reuters.com/article/health-coronavirus-vaccine/special- report-countries-companies-risk-billions-in-race-for-coronavirus- vaccine-idUSL2N2CF0JG. China is ahead of the curve. China weakness has always been with real facts.  https://www.fiercepharma.com/vaccines/china-s-cansino-pushes- coronavirus-vaccine-into-clinical-testing-as-moderna-doses-1st “The green light was doled out very quickly. It was only Tuesday when CanSino said it had filed the pre-IND review application for the vaccine to authorities and was in the process of a rolling submission of technical documents. CanSino’s candidate, dubbed Ad5-nCoV, uses its adenovirus- based viral vector vaccine platform. In 2017, the same technology helped the company earn a Chinese nod for its Ebola vaccine, which was the first Ebola shot approved anywhere based on the strain behind the deadly epidemic in West Africa in 2014.  Trial of COVID19 drug back by the Military - https://twitter.com/dockaurg/status/1262018934569664515  Last 10K filed was 2017 - https://fintel.io/filings/us/casbf  Only 2018 showed revenue
SYMVIVIO CORPORATION  Early VC company working with Canadian government - https://pitchbook.com/profiles/company/185411-98#funding (Key investor - National Research Council Canada  https://www.dnb.com/business-directory/company- profiles.symvivo_corporation.31108ce6e17eb52f4e64c097dc36f2f7.html “Symvivo Corporation is in Burnaby, BC, Canada and is part of the Biotechnology Research Services Industry. Symvivo Corporation has 3 total employees across all of its locations and generates $580,698 in sales (USD).”  Small venture capital and pre-trials - https://www.trialsitenews.com/ubc- dalhousie-university-commence-study-of-the-bactrl-spike-vaccine-targeting- covid-19/ “According to one profile, the venture has raised $2 million from a local early state venture investor and $100K from a National Research Council. Founder Graves started the company, along with Mark Fox—a friend from undergrad—as he realized “he sucked” at research but desired to leverage his scientific degree in meaningful ways. Graves and Fox sought to develop a platform that could accelerate drug development by focusing on the discovery—developing patents for aspects of the drug delivery process that could be licensed to drug makers”
NOVOVAX  A small group of scientists, execs, and VCs are $277 million richer as their companies race to create a coronavirus vaccine. Here are 7 who have raked in huge sums. - https://markets.businessinsider.com/news/stocks/coronavirus-drugmakers-moderna- gilead-novavax-stock-price-profit-millions-shareholders-2020-2-1028949761  Stock sales due to trials - https://www.bizjournals.com/washington/news/2020/05/20/novavax-prepares-stock- sale-as-covid-19-vaccine.html  https://finance.yahoo.com/news/novavax-nvax-stock-come-too-224659672.html “Vaccine specialist Novavax (NVAX) stepped up to the plate, and hit the ball out of the park yet again. Investors had already enjoyed some pretty hefty gains in 2020 before more positive developments sent the stock into the stratosphere. Last week, news that Novavax had received a $384 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI) to support the development of its COVID-19 vaccine candidate, NVX-CoV2373, resulted in a 133% addition to the share price”  Coalition Preparedness https://cepi.net/about/whoweare/ - CEPI has secured financial investment from the Governments of Australia, Belgium, Canada, Denmark, Ethiopia, Finland, Germany, Japan, the Kingdom of Saudi Arabia, the Netherlands, Norway, the UK and Switzerland, as well as the Bill & Melinda Gates Foundation, and Wellcome. The European Commission provides substantial financial contributions to support relevant projects through its mechanisms. CEPI has also received donations from the private sector and individuals through the UN Foundation’s COVID-19 Solidarity Response Fund to support our COVID-19 vaccine development efforts.
CUREVAC  As the race to develop a coronavirus vaccine intensifies, one player— German drugmaker CureVac—is backed by particularly deep pockets. CureVac, which is in the headlines amid rumors that the U.S. government offered funding to lure its research exclusively to America, counts one of Germany’s richest entrepreneurs, Mexican shopping mall tycoons and the Bill and Melinda Gates Foundation among its investors. https://www.forbes.com/sites/martaorosz/2020/03/16/these-are-the- billionaire-investors-behind-german-drugmakers-developing-a- coronavirus-vaccine/#78c83f841fb8  Regulators / Germany https://www.ft.com/content/7409dbae-6b4f- 4be0-ba75-46ed52e951ae  In the race to find a medical breakthrough to the pandemic, the startup, CureVac, said earlier this month that its proprietary technology has found suitable candidates that could lead to a treatment, and that it aims to start clinical trials in early summer. CureVac has received funding from the Bill & Melinda Gates Foundation. - https://fortune.com/2020/03/16/coronavirus-cure- trump-businesses-biotech/
GENEREX  Manufacturing of peptide - https://www.globenewswire.com/news- release/2020/05/04/2026744/0/en/Generex-Biotechnology- Initiates-Peptide-Manufacturing-for-Ii-Key-SARS-CoV-2-Peptide- Vaccine-Against-the-COVID-19-Pandemic.html  Stock/Generex- https://www.fool.com/investing/2020/05/17/is- buying-a-basket-loaded-with-every-coronavirus-v.aspx “BIO, the biggest trade group representing the biotechnology industry, currently lists 28 companies that are actively involved in developing COVID-19 vaccines. Here are the 21 of those drugmakers that are publicly traded:”
VAXART  SOUTH SAN FRANCISCO, Calif., May 20, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”) (NASDAQ: VXRT), a clinical- stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has selected its lead COVID-19 vaccine candidate and has contracted with KindredBio to manufacture bulk vaccine under cGMP to complement the manufacturing capacity of partner Emergent BioSolutions https://www.globenewswire.com/news- release/2020/05/20/2036357/0/en/Vaxart-Announces-Selection-of- its-Oral-COVID-19-Vaccine-Lead-Candidate.html  Funding issues - https://seekingalpha.com/article/4334623-vaxarts- coronavirus-stock-bump-is-unlikely-to-continue-exit-now-be-long  Cash on hand - https://www.fool.com/investing/2020/04/28/why- vaxart-stock-slumped-today.aspx  Partnerships - https://observer.com/2020/05/covid-19-vaccine- moderna-results-new-progress/
MEDICAGO  Quebec Funding - https://www.canadianmanufacturing.com/research-and- development/government-of-quebec-providing-7m-to- medicagos-covid-19-vaccine-development-249412/  Animal Trials - https://www.sttinfo.fi/tiedote/medicago- announces-positive-results-in-animal-trials-for-its-vaccine- candidate-against-covid- 19?publisherId=58763726&releaseId=69881188  Collaborative project of more than $1.2 million using artificial intelligence to optimize the production of vaccines, announced by CQDM and Medicago R&D - https://www.newswire.ca/news- releases/collaborative-project-of-more-than-1-2-million-using- artificial-intelligence-to-optimize-the-production-of-vaccines- announced-by-cqdm-and-medicago-r-amp-d-859733879.html
TAKIS  “TAKIS SRL is located in ROMA, ROMA, Italy and is part of the Scientific Research & Development Services Industry. TAKIS SRL has 15 employees at this location and generates $1.78 million in sales (USD). There are 4 companies in the TAKIS SRL corporate family. https://www.dnb.com/business-directory/company- profiles.takis_srl.1084976c4f88cf6ddd4089044968c511.html  Startup - https://www.forbes.com/sites/giacomotognini/2020/04/21/inside -the-tiny-italian-biotech-startup-racing-to-develop-a- coronavirus-vaccine/#b686e172c106  Funding - https://finance.yahoo.com/news/applied-dna-takis- biotech-announce-070000273.html
UPDATE – VACCINES / DEVELOPMENT Source - “” https://www.healthline.com/healt h-news/heres-exactly-where- were-at-with-vaccines-and- treatments-for-covid-19
VACCINES DEVELOPMENT  GSK - https://indianexpress.com/article/coronavirus/coronavirus-covid-19-vaccine-glaxosmithkline-oxford- astrazeneca-moderna-clover-status-check-6469474/  Vaccine Tracker - https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html  Gavi organization funding from sources like Bill Gates and world governments - https://www.biopharma- reporter.com/Article/2020/06/17/Gavi-receives-billions-in-funding  Gates and Inovio - https://www.newsbreak.com/missouri/kansas-city/news/0OfXdfSR/a-potential-coronavirus- vaccine-funded-by-bill-gates-is-set-to-begin-testing-in-people-with-the-first-patient-expected-to-get-it- today
ALTIMUNE  “Shares of Altimmune (ALT) - Get Report soared Thursday after the clinical-stage biopharmaceutical company announced the next step in development of its coronavirus vaccine AdCovid. “In collaboration with the University of Alabama at Birmingham, we have commenced preclinical testing of candidates for our Covid- 19 vaccine, AdCovid,” the company said in a statement. https://www.thestreet.com/investing/altimmune-coronavirus- vaccine-preclinical-trial  Former Pfizer board director appointed to Altimmune - https://www.reuters.com/companies/ALT.OQ
TESTING  COVID19 – Testing “It uses a simple assay containing plasmonic gold nanoparticles to detect a color change when the virus is present. The test does not require the use of any advanced laboratory techniques, such as those commonly used to amplify DNA, for analysis. The authors published their work last week in the American Chemical Society’s nanotechnology journal ACS Nano. "Based on our preliminary results, we believe this promising new test may detect RNA material from the virus as early as the first day of infection. Additional studies are needed, however, to confirm whether this is indeed the case,” said study leader Dipanjan Pan, PhD, professor of diagnostic radiology and nuclear medicine and pediatrics at UMSOM.” https://www.umaryland.edu/news/archived-news/may-2020/covid-19- results-in-10-minutes-umb-studies-rapid-test.php or https://www.nextbigfuture.com/2020/05/ten-minute-covid-19- detection-test-using- nanoparticles.html?utm_source=feedburner&utm_medium=feed&utm_ campaign=Feed%3A+blogspot%2Fadvancednano+%28nextbigfuture% 29
TESTING KITS Source - https://www.medtechdive.com/news/coronavirus-tests-home-collection-quest-diagnostics- letsgetchecked/578837/ The cost is $129 per kit!
GLOBAL MARKET / TESTING Source - https://www.globenewswire.com/news-release/2020/06/01/2041269/0/en/Global-COVID-19-diagnostic-testing-market-to-amass-USD-44481-8-million-in-2020.html • Additional costs to already strapped healthcare system • Private insurance companies and their coverage in terms of their testing. This could mean a rise in premiums • Consumers could be out of pocket about $129 per test.
TREATMENT OPTIONS
ANTIBODIES  “Much remains to be learnt about the immunological responses to SARS-CoV-2. Nevertheless, it is becoming clear that antibodies taken from the blood serum of people who have recovered from COVID-19 can be used for treatment by being transfused into other people who have the disease”Source - https://www.nature.com/articles/d41586-020-01816-5  Disappearance of antibodies 2-3 months - https://www.medscape.com/viewarticle/932671  “Those who did not have a bad case of COVID-19 lose antibodies faster. Forty percent of asymptomatic individuals became seronegative and 12.9% of the symptomatic group became negative for IgG in the early convalescent phase. In addition, asymptomatic individuals exhibited lower levels of 18 pro- and anti-inflammatory cytokines. These data suggest that asymptomatic individuals had a weaker immune response to SARS- CoV-2 infection.mThe research, published in Nature Medicine on June 18, highlights the risks of using COVID-19 ‘immunity passports’ and supports the prolonged use of public health interventions such as social distancing and isolating high-risk groups This seems to indicate that our better bet is t-cell-related therapies and vaccines and hygiene and social distancing.  Avoid getting together with larger groups  Stay 6-10 ten feet apart if at all possible  clean your hands every hour  Source - https://www.nextbigfuture.com/2020/06/coronavirus-antibody-immunity-fades-by-70-within-2-3- months.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+blogspot%2Fadvancednano+%28nextbigfuture%29
GENE RESEARCH  Genome sequencing - https://globalnews.ca/news/7072424/alberta-researchers-genome-sequence-covid-19/  AI and Genome sequencing - http://www.genomequebec.com/486-en/news-covid-19-unprecedented- research-combining-genomics-and-artificial-intelligenceicial-intelligence/  Blood type and genome - https://directorsblog.nih.gov/2020/06/18/genes-blood-type-tied-to-covid-19-risk- of-severe-disease/
MITIGATION  Shutting down an economy should be last resort  Private sector is driven by cash flow.  The focus should be on infrastructure, getting goods to market, supply chain, advance technology and reforming of government - https://www.slideshare.net/paulyoungcga/canada-gdp-and-economy-truth-and-what-needs-to-change  All levels of government should review their pandemic responses to ensure they have updated their playbook  Annual audits of risk and crisis management should be completed each year - https://www.slideshare.net/paulyoungcga/the-role-of-operational-and- performancebased-auditing-on-government-and-the-private-sector  WHO needs to provide reports on virus threats including what needs to be done to mitigate the spread  https://www.slideshare.net/paulyoungcga/crisis-management-how-best-to-managed-a-crisis  More coordination by the WHO with all government including monthly status calls around threats  Reporting should also be provided on the threats including performance audits of various WHO programs  Mitigating the spread is to ensure healthcare is provided with the necessary equipment - https://www.cdc.gov/coronavirus/2019-ncov/hcp/ppe-strategy/index.html  Sterilization methods of equipment and masks - https://www.inthehammer.com/hamilton-firms-technology-addresses-covid- waste-and-ppe-shortage  Protecting the most vulnerable  Screening at hospitals and long-term care facilities  Restricting the movement of staff between facilities
UPDATE – JUNE 23, 2020 TO JULY 1, 2O20  State of affairs with COVID19 - https://www.healthline.com/health-news/heres-exactly-where-were-at-with-vaccines- and-treatments-for-covid-19  Line is forming for the vaccine - https://www.sciencemag.org/news/2020/06/line-forming-covid-19-vaccine-who- should-be-front  You cannot shut down the economy, but all levels of government including the private sector need to take mitigating steps - https://www.slideshare.net/paulyoungcga/transforming-the-economy-postcovid19-canada-and-the-world  China is using the pandemic to make changes with laws for Hong Kong - https://www.cnn.com/2020/07/01/asia/hong-kong-national-security-law-intl-hnk/index.html  USA buys up key drug - https://globalnews.ca/news/7127951/us-remdesivir-supply-coronavirus/  Antibody treatment - https://www.cnn.com/2020/06/26/health/antibody-therapies-covid-19-update- wellness/index.html
VACCINES, HEALTH AND SAFETY AND TESTING UPDATE  USA clinical trials - https://globalnews.ca/news/7178006/us-coronavirus-vaccine-testing/  Human trials in Quebec - https://www.cbc.ca/news/health/human-trials-covid-19-vaccine-candidate-quebec- 1.5648648  World and treatment of COVID19 - https://www.healthline.com/health-news/heres-exactly-where-were-at-with- vaccines-and-treatments-for-covid-19#Antivirals  Vaccines Trials - https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html  Mobile testing kits - https://www.thestar.com/business/2020/07/09/guelph-companys-mobile-covid-19-test-kit-hits- market-and-heads-for-norther-ontario.html  Workplace measures - https://www.ontario.ca/page/develop-your-covid-19-workplace-safety-plan or http://www.worksafesask.ca/covid-19/conducting-a-hazard-assessment-and-developing-a-safety-plan/  Mobile workers - https://www.carsondesign.com/2017/12/designing-your-office-space-for-the-mobile-workforce/
TRAINING AND DEVELOPMENT  If you like to learn more about trade and/or other subjects as part of your professional learning and development then feel free to review my material on https://www.udemy.com/ (search Paul Young CPA CGA)  These subjects address how to fixed issues with housing and/or systemic issues related to economy including government policies
SUMMARY  There are many companies involved with research and development of COVID19 vaccine - https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=677  Bill and Melinda Gates Foundation are playing a key role with funding and manufacturing - https://www.geekwire.com/2020/gates-foundation-commits-50m- covid-19-vaccine-initiative-total-funding-now-tops-300m/ (Funding is now over $300M (USD)  There are allot of startups involved. Various Canadian governments have been funding VC companies related to biotech research  There appears to be lack of progress reports on the state of affairs when it comes to government money going to vaccinations R&D - https://cmajnews.com/2020/05/20/coronavirus-1095847/  There is allot of speculator investments going on with biotech companies as part of reaping the rewards when vaccines go to market.  Major pharma continues to work with government, institution, labs, Tech, etc. https://www.bioworld.com/articles/435263-astrazeneca-moving-at-warp-speed-with- 12b-in-barda-funding-for-covid-19-vaccine  Economy could see periods of slow growth for years - https://www.slideshare.net/paulyoungcga/transforming-the-economy-postcovid19- canada-and-the-world or https://www.investmentexecutive.com/news/research-and- markets/covid-19-to-reshape-economy-society-moodys/

More Related Content

PPTX
Race for COVID19 Vaccine and Treatments
bypaul young cpa, cga
 
PPTX
Race for COVID19 Vaccine
bypaul young cpa, cga
 
PPTX
How best to Manage a Pandemic| January 25, 2021
bypaul young cpa, cga
 
PPTX
How best to Manage a Pandemic| February 8, 2021
bypaul young cpa, cga
 
PPTX
How best to Managed a Pandemic| February 14, 2021
bypaul young cpa, cga
 
PPTX
How best to Management a Pandemic - December 1, 2020
bypaul young cpa, cga
 
PPTX
Management of a Virus| COVID19
bypaul young cpa, cga
 
PPTX
How best to Manage a Pandemic - December 6, 2020
bypaul young cpa, cga
 
Race for COVID19 Vaccine and Treatments
bypaul young cpa, cga
 
Race for COVID19 Vaccine
bypaul young cpa, cga
 
How best to Manage a Pandemic| January 25, 2021
bypaul young cpa, cga
 
How best to Manage a Pandemic| February 8, 2021
bypaul young cpa, cga
 
How best to Managed a Pandemic| February 14, 2021
bypaul young cpa, cga
 
How best to Management a Pandemic - December 1, 2020
bypaul young cpa, cga
 
Management of a Virus| COVID19
bypaul young cpa, cga
 
How best to Manage a Pandemic - December 6, 2020
bypaul young cpa, cga
 

What's hot

PPTX
Management of COVID19 (Pandemic)
bypaul young cpa, cga
 
PPTX
How to best Managed a Pandemic| Crisis Management
bypaul young cpa, cga
 
PPTX
How best to Management a Pandemic| Geopolitical Event| November 25, 2020
bypaul young cpa, cga
 
PPTX
How Best to Managed a Pandemic| Crisis Management| December 22, 2020
bypaul young cpa, cga
 
PPTX
Management a virus
bypaul young cpa, cga
 
PPTX
How to best manage a Pandemic| Crisis Management| December 20,2020
bypaul young cpa, cga
 
PPTX
Management of a Pandemic| Analysis and Commentary
bypaul young cpa, cga
 
PPTX
Pandemic| Management of a Crisis
bypaul young cpa, cga
 
PPTX
Management of a Pandemic Crisis
bypaul young cpa, cga
 
PPTX
Management of a Pandemic| COVID-19| Analysis and Commentary
bypaul young cpa, cga
 
PPTX
Management of Pandemic
bypaul young cpa, cga
 
PPTX
How best to Manage a Pandemic| January 6, 2020
bypaul young cpa, cga
 
PPTX
How best to Manage a Pandemic| December 30, 2020
bypaul young cpa, cga
 
PPTX
Management of a Pandemic| COVID-19| Canada and the World
bypaul young cpa, cga
 
PPTX
Crisis Management| Pandemic| COVID19
bypaul young cpa, cga
 
PPTX
Management of Pandemic| November 19, 2020| Analysis
bypaul young cpa, cga
 
PDF
Pediatric vaccines market, doses, immunization, cases and forecast worldwide ...
byRenub Research
 
PDF
Life Sciences Trends for 2019
byKumaraguru Veerasamy
 
PPTX
Megafund for Rare Diseases
byEURORDIS Rare Diseases Europe
 
PDF
Adult Vaccines Market, Company Adult Vaccines Sales, Country Adult Vaccines -...
byRenub Research
 
Management of COVID19 (Pandemic)
bypaul young cpa, cga
 
How to best Managed a Pandemic| Crisis Management
bypaul young cpa, cga
 
How best to Management a Pandemic| Geopolitical Event| November 25, 2020
bypaul young cpa, cga
 
How Best to Managed a Pandemic| Crisis Management| December 22, 2020
bypaul young cpa, cga
 
Management a virus
bypaul young cpa, cga
 
How to best manage a Pandemic| Crisis Management| December 20,2020
bypaul young cpa, cga
 
Management of a Pandemic| Analysis and Commentary
bypaul young cpa, cga
 
Pandemic| Management of a Crisis
bypaul young cpa, cga
 
Management of a Pandemic Crisis
bypaul young cpa, cga
 
Management of a Pandemic| COVID-19| Analysis and Commentary
bypaul young cpa, cga
 
Management of Pandemic
bypaul young cpa, cga
 
How best to Manage a Pandemic| January 6, 2020
bypaul young cpa, cga
 
How best to Manage a Pandemic| December 30, 2020
bypaul young cpa, cga
 
Management of a Pandemic| COVID-19| Canada and the World
bypaul young cpa, cga
 
Crisis Management| Pandemic| COVID19
bypaul young cpa, cga
 
Management of Pandemic| November 19, 2020| Analysis
bypaul young cpa, cga
 
Pediatric vaccines market, doses, immunization, cases and forecast worldwide ...
byRenub Research
 
Life Sciences Trends for 2019
byKumaraguru Veerasamy
 
Megafund for Rare Diseases
byEURORDIS Rare Diseases Europe
 
Adult Vaccines Market, Company Adult Vaccines Sales, Country Adult Vaccines -...
byRenub Research
 

Similar to COVID19| What's next

PPTX
Race for COVID19 Vaccines and Treatments
bypaul young cpa, cga
 
PPTX
COVID19| Race to Vaccine and Expediting Testing| June 2020
bypaul young cpa, cga
 
PPTX
LEVERAGING PRIVATE-PUBLIC PARTNERSHIPS IN COVID-19 PANDEMIC RESPONSE
byiQHub
 
PDF
COVID-19 Vaccine Deals
byKumaraguru Veerasamy
 
PDF
COVID-19 Therapies and Vaccines
byDenis Cohen-Tannoudji
 
DOCX
Covid 19 vaccine profit race
byMukesh Ray
 
PDF
The 10 most trusted vaccine solution providers, 2020
byMerry D'souza
 
PPTX
Ppt COVID vaccination
byShinjan Patra
 
PPTX
COVID vaccination and prevention strategies
byShinjan Patra
 
PDF
The Future Landscape of Covid-19 Vaccine Market
byMehdiMehdiyev4
 
PPTX
Investment_Mapping_v7_web for pharmas manu
byssuser796efb
 
PPTX
Covid 19 vaccines ,ramesh c k
byDr RAMESH C K
 
PPTX
Case study of clinical research on COVID-19.pptx
byramkris90q
 
PPTX
Canada| Biotech and Pharmaceutical| Manufacturing
bypaul young cpa, cga
 
PDF
5 Most Trusted Vaccine Manufacturing Companies in 2023.pdf
byinsightscare
 
Race for COVID19 Vaccines and Treatments
bypaul young cpa, cga
 
COVID19| Race to Vaccine and Expediting Testing| June 2020
bypaul young cpa, cga
 
LEVERAGING PRIVATE-PUBLIC PARTNERSHIPS IN COVID-19 PANDEMIC RESPONSE
byiQHub
 
COVID-19 Vaccine Deals
byKumaraguru Veerasamy
 
COVID-19 Therapies and Vaccines
byDenis Cohen-Tannoudji
 
Covid 19 vaccine profit race
byMukesh Ray
 
The 10 most trusted vaccine solution providers, 2020
byMerry D'souza
 
Ppt COVID vaccination
byShinjan Patra
 
COVID vaccination and prevention strategies
byShinjan Patra
 
The Future Landscape of Covid-19 Vaccine Market
byMehdiMehdiyev4
 
Investment_Mapping_v7_web for pharmas manu
byssuser796efb
 
Covid 19 vaccines ,ramesh c k
byDr RAMESH C K
 
Case study of clinical research on COVID-19.pptx
byramkris90q
 
Canada| Biotech and Pharmaceutical| Manufacturing
bypaul young cpa, cga
 
5 Most Trusted Vaccine Manufacturing Companies in 2023.pdf
byinsightscare
 

More from paul young cpa, cga

PPTX
Retail Sales and Consumer Spending Analysis and Commentary - July 2023.pptx
bypaul young cpa, cga
 
PPTX
Addressing issues with the Public Sector Governance Model.pptx
bypaul young cpa, cga
 
PPTX
Global Housing Market Analysis and Commentary- September 2023.pptx
bypaul young cpa, cga
 
PPTX
What is next for the Mining Sector.pptx
bypaul young cpa, cga
 
PPTX
Manufacturing Sector – United States – August 2023.pptx
bypaul young cpa, cga
 
PPTX
Stock Market Analysis and Commentary for WE September 15 2023.pptx
bypaul young cpa, cga
 
PPTX
Manufacturing Sector – Canada – September 2023.pptx
bypaul young cpa, cga
 
PPTX
Electricity Analysis - Canada and the OECD - June 2023.pptx
bypaul young cpa, cga
 
PPTX
Logistics Warehousing Transportation and Distrbution Analysis and Commentary ...
bypaul young cpa, cga
 
PPTX
Retail Sales and Consumer Spending Analysis and Commentary - United States - ...
bypaul young cpa, cga
 
PPTX
How to improve the Governance Model for the Public Sector - United States - S...
bypaul young cpa, cga
 
PPTX
What is next for Agriculture Sector - August 2023.pptx
bypaul young cpa, cga
 
PPTX
Biotech Pharmaceutical Medical Equipment and Supplies - Analysis - September ...
bypaul young cpa, cga
 
PPTX
Better Public Safety Management using Analytics - September 2023.pptx
bypaul young cpa, cga
 
PPTX
Stock Market Analysis and Commentary for WE September 9 2023.pptx
bypaul young cpa, cga
 
PPTX
Workforce Planning and Employment Analysis - August 2023.pptx
bypaul young cpa, cga
 
PPTX
Global Automotive - Analysis and Commentary - August 2023.pptx
bypaul young cpa, cga
 
PPTX
Global (Mining Oil and Gas Forestry and Agriculture) Analysis and Commentary ...
bypaul young cpa, cga
 
PPTX
World Merchandise Trade – September 2023.pptx
bypaul young cpa, cga
 
PPTX
What is next for the Forestry Sector and Lumber Production - September 2023.pptx
bypaul young cpa, cga
 
Retail Sales and Consumer Spending Analysis and Commentary - July 2023.pptx
bypaul young cpa, cga
 
Addressing issues with the Public Sector Governance Model.pptx
bypaul young cpa, cga
 
Global Housing Market Analysis and Commentary- September 2023.pptx
bypaul young cpa, cga
 
What is next for the Mining Sector.pptx
bypaul young cpa, cga
 
Manufacturing Sector – United States – August 2023.pptx
bypaul young cpa, cga
 
Stock Market Analysis and Commentary for WE September 15 2023.pptx
bypaul young cpa, cga
 
Manufacturing Sector – Canada – September 2023.pptx
bypaul young cpa, cga
 
Electricity Analysis - Canada and the OECD - June 2023.pptx
bypaul young cpa, cga
 
Logistics Warehousing Transportation and Distrbution Analysis and Commentary ...
bypaul young cpa, cga
 
Retail Sales and Consumer Spending Analysis and Commentary - United States - ...
bypaul young cpa, cga
 
How to improve the Governance Model for the Public Sector - United States - S...
bypaul young cpa, cga
 
What is next for Agriculture Sector - August 2023.pptx
bypaul young cpa, cga
 
Biotech Pharmaceutical Medical Equipment and Supplies - Analysis - September ...
bypaul young cpa, cga
 
Better Public Safety Management using Analytics - September 2023.pptx
bypaul young cpa, cga
 
Stock Market Analysis and Commentary for WE September 9 2023.pptx
bypaul young cpa, cga
 
Workforce Planning and Employment Analysis - August 2023.pptx
bypaul young cpa, cga
 
Global Automotive - Analysis and Commentary - August 2023.pptx
bypaul young cpa, cga
 
Global (Mining Oil and Gas Forestry and Agriculture) Analysis and Commentary ...
bypaul young cpa, cga
 
World Merchandise Trade – September 2023.pptx
bypaul young cpa, cga
 
What is next for the Forestry Sector and Lumber Production - September 2023.pptx
bypaul young cpa, cga
 

Recently uploaded

PPTX
ECONOMIC GROWTH, DEVELOPMENT AND GLOBALISATIONS.pptx
bykamosekanka
 
PDF
Understanding How Abhay Bhutada Foundation Fulfills SEBI ESG Criteria
byRaj Kumble
 
DOCX
AHRFD Institutional Crypto Holdings Surge: Bitmine's $13.4B Ethereum Strategy
byAHRFD
 
PPT
Pertemuan 4, Approaches to Internal Audit.ppt
bySantyo Nugroho
 
PDF
Top 10 SBLC Providers in the UK 2025 | TRG Ranks #2
byTRG Venture Capital International Investment G.P. Limited:
 
PDF
Veritas Interim report 1 January–30 September 2025
byVeritas Eläkevakuutus - Veritas Pensionsförsäkring
 
PDF
A PREDICTION FOR THE INTRODUCTION AND IMPLEMENTATION OF A NEW FINANCIAL SYSTE...
bynakasotoshimoto
 
PPTX
CERI III Transparency in Public Sector Accounting -Prof Oyedokun.pptx
byGodwin Emmanuel Oyedokun MBA MSc PhD FCA FCTI FCNA CFE FFAR
 
PDF
IBERO MINING CORP Copper is hot. Portugal's Got it
byAgoracom Small Caps
 
PDF
A Closed-Loop Internet–Blockchain Hybrid_ The Next Evolution of Cloud Securit...
byStevenHeizmannCPA
 
PPTX
The Best Trust Converter Tools Application
bywalterfierz2
 
PPTX
Accounting Equation (Persamaan Dasar Akuntansi).pptx
byGraceMelisa3
 
PPTX
一比一原版(UM毕业证书)穆尔西亚大学毕业证如何办理成绩单网上可查学历认证
by南澳大利亚大学学历认证【Q微号:1954 292 140】研究生文凭(UniSA毕业证成绩单)
 
PPTX
time value of money, investment criteria and project rating index.pptx
byYogesh Dixit
 
DOCX
JPMorgan's Crypto Revolution: How Niufo Leads the Digital Asset Evolution
byNiufo
 
PPTX
Estate Planning in a Global Context.pptx
byHammadUlHaque1
 
DOCX
Why PayPal Accounts Dominate the Digital Payment Industry.docx
byBEST IT SMM
 
PPTX
Budget_and_Financial_Reporting_for_the_Enterprise 6.pptx
byRillaGantino2
 
PPTX
What is a business information report, and what information would I get in th...
byCred hive
 
PPTX
Framework COBIT 5 Materi Audit Sistem Informasi
bySantyo Nugroho
 
ECONOMIC GROWTH, DEVELOPMENT AND GLOBALISATIONS.pptx
bykamosekanka
 
Understanding How Abhay Bhutada Foundation Fulfills SEBI ESG Criteria
byRaj Kumble
 
AHRFD Institutional Crypto Holdings Surge: Bitmine's $13.4B Ethereum Strategy
byAHRFD
 
Pertemuan 4, Approaches to Internal Audit.ppt
bySantyo Nugroho
 
Top 10 SBLC Providers in the UK 2025 | TRG Ranks #2
byTRG Venture Capital International Investment G.P. Limited:
 
Veritas Interim report 1 January–30 September 2025
byVeritas Eläkevakuutus - Veritas Pensionsförsäkring
 
A PREDICTION FOR THE INTRODUCTION AND IMPLEMENTATION OF A NEW FINANCIAL SYSTE...
bynakasotoshimoto
 
CERI III Transparency in Public Sector Accounting -Prof Oyedokun.pptx
byGodwin Emmanuel Oyedokun MBA MSc PhD FCA FCTI FCNA CFE FFAR
 
IBERO MINING CORP Copper is hot. Portugal's Got it
byAgoracom Small Caps
 
A Closed-Loop Internet–Blockchain Hybrid_ The Next Evolution of Cloud Securit...
byStevenHeizmannCPA
 
The Best Trust Converter Tools Application
bywalterfierz2
 
Accounting Equation (Persamaan Dasar Akuntansi).pptx
byGraceMelisa3
 
一比一原版(UM毕业证书)穆尔西亚大学毕业证如何办理成绩单网上可查学历认证
by南澳大利亚大学学历认证【Q微号:1954 292 140】研究生文凭(UniSA毕业证成绩单)
 
time value of money, investment criteria and project rating index.pptx
byYogesh Dixit
 
JPMorgan's Crypto Revolution: How Niufo Leads the Digital Asset Evolution
byNiufo
 
Estate Planning in a Global Context.pptx
byHammadUlHaque1
 
Why PayPal Accounts Dominate the Digital Payment Industry.docx
byBEST IT SMM
 
Budget_and_Financial_Reporting_for_the_Enterprise 6.pptx
byRillaGantino2
 
What is a business information report, and what information would I get in th...
byCred hive
 
Framework COBIT 5 Materi Audit Sistem Informasi
bySantyo Nugroho
 

COVID19| What's next

  • 1.
    RACE TO COVID19VACCINE AND TESTING PAUL YOUNG CPA CGA JULY 15, 2020
  • 2.
    PAUL YOUNG CPACGA – BIO September 9, 2014 • CPA, CGA • Financial Solutions • SME – Risk Management • SME – Emerging Technology • SME – Business Process Change • SME – Close, Consolidate and Reporting • SME – Public Policy • SME – Financial Solutions • SME – Supply Chain Management Contact – [email protected]
  • 3.
    INTRODUCTION This presentation takesa look at what is happening with the COVID19 vaccine development.
  • 4.
    AGENDA  Pharma andVaccines development  Key Companies  CANSINO BIOLOGICS INC.(6185)  Symvivio Corporation  Novovax  CureVac  Generex  Vaxart  Medicago  Takis  Altimmune  Testing  Testing Kits  Global Market / Testing  Effective Treatments  Antibodies  Mitigation  Summary
  • 5.
    MAJOR PLAYERS /VACCINES DEVELOPMENT
  • 6.
  • 7.
    CANSINO BIOLOGICS INC.(6185)  100% ofthe revenue is in China - https://www.marketscreener.com/CANSINO-BIOLOGICS-INC- 59318312/company/  The chair is McGill graduate. https://www.marketscreener.com/business- leaders/Xue-Feng-Yu-0DD2L9-E/biography/ Trudeau attended McGill and McGill has high Chinese enrolment - https://www.mcgill.ca/international/channels/news/mcgill-news-china- tops-international-enrolment-mcgill-first-time-291377  J&J and Casino have similar vaccine - https://www.reuters.com/article/health-coronavirus-vaccine/special- report-countries-companies-risk-billions-in-race-for-coronavirus- vaccine-idUSL2N2CF0JG. China is ahead of the curve. China weakness has always been with real facts.  https://www.fiercepharma.com/vaccines/china-s-cansino-pushes- coronavirus-vaccine-into-clinical-testing-as-moderna-doses-1st “The green light was doled out very quickly. It was only Tuesday when CanSino said it had filed the pre-IND review application for the vaccine to authorities and was in the process of a rolling submission of technical documents. CanSino’s candidate, dubbed Ad5-nCoV, uses its adenovirus- based viral vector vaccine platform. In 2017, the same technology helped the company earn a Chinese nod for its Ebola vaccine, which was the first Ebola shot approved anywhere based on the strain behind the deadly epidemic in West Africa in 2014.  Trial of COVID19 drug back by the Military - https://twitter.com/dockaurg/status/1262018934569664515  Last 10K filed was 2017 - https://fintel.io/filings/us/casbf  Only 2018 showed revenue
  • 8.
    SYMVIVIO CORPORATION  Early VCcompany working with Canadian government - https://pitchbook.com/profiles/company/185411-98#funding (Key investor - National Research Council Canada  https://www.dnb.com/business-directory/company- profiles.symvivo_corporation.31108ce6e17eb52f4e64c097dc36f2f7.html “Symvivo Corporation is in Burnaby, BC, Canada and is part of the Biotechnology Research Services Industry. Symvivo Corporation has 3 total employees across all of its locations and generates $580,698 in sales (USD).”  Small venture capital and pre-trials - https://www.trialsitenews.com/ubc- dalhousie-university-commence-study-of-the-bactrl-spike-vaccine-targeting- covid-19/ “According to one profile, the venture has raised $2 million from a local early state venture investor and $100K from a National Research Council. Founder Graves started the company, along with Mark Fox—a friend from undergrad—as he realized “he sucked” at research but desired to leverage his scientific degree in meaningful ways. Graves and Fox sought to develop a platform that could accelerate drug development by focusing on the discovery—developing patents for aspects of the drug delivery process that could be licensed to drug makers”
  • 9.
    NOVOVAX  A smallgroup of scientists, execs, and VCs are $277 million richer as their companies race to create a coronavirus vaccine. Here are 7 who have raked in huge sums. - https://markets.businessinsider.com/news/stocks/coronavirus-drugmakers-moderna- gilead-novavax-stock-price-profit-millions-shareholders-2020-2-1028949761  Stock sales due to trials - https://www.bizjournals.com/washington/news/2020/05/20/novavax-prepares-stock- sale-as-covid-19-vaccine.html  https://finance.yahoo.com/news/novavax-nvax-stock-come-too-224659672.html “Vaccine specialist Novavax (NVAX) stepped up to the plate, and hit the ball out of the park yet again. Investors had already enjoyed some pretty hefty gains in 2020 before more positive developments sent the stock into the stratosphere. Last week, news that Novavax had received a $384 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI) to support the development of its COVID-19 vaccine candidate, NVX-CoV2373, resulted in a 133% addition to the share price”  Coalition Preparedness https://cepi.net/about/whoweare/ - CEPI has secured financial investment from the Governments of Australia, Belgium, Canada, Denmark, Ethiopia, Finland, Germany, Japan, the Kingdom of Saudi Arabia, the Netherlands, Norway, the UK and Switzerland, as well as the Bill & Melinda Gates Foundation, and Wellcome. The European Commission provides substantial financial contributions to support relevant projects through its mechanisms. CEPI has also received donations from the private sector and individuals through the UN Foundation’s COVID-19 Solidarity Response Fund to support our COVID-19 vaccine development efforts.
  • 10.
    CUREVAC  As therace to develop a coronavirus vaccine intensifies, one player— German drugmaker CureVac—is backed by particularly deep pockets. CureVac, which is in the headlines amid rumors that the U.S. government offered funding to lure its research exclusively to America, counts one of Germany’s richest entrepreneurs, Mexican shopping mall tycoons and the Bill and Melinda Gates Foundation among its investors. https://www.forbes.com/sites/martaorosz/2020/03/16/these-are-the- billionaire-investors-behind-german-drugmakers-developing-a- coronavirus-vaccine/#78c83f841fb8  Regulators / Germany https://www.ft.com/content/7409dbae-6b4f- 4be0-ba75-46ed52e951ae  In the race to find a medical breakthrough to the pandemic, the startup, CureVac, said earlier this month that its proprietary technology has found suitable candidates that could lead to a treatment, and that it aims to start clinical trials in early summer. CureVac has received funding from the Bill & Melinda Gates Foundation. - https://fortune.com/2020/03/16/coronavirus-cure- trump-businesses-biotech/
  • 11.
    GENEREX  Manufacturing ofpeptide - https://www.globenewswire.com/news- release/2020/05/04/2026744/0/en/Generex-Biotechnology- Initiates-Peptide-Manufacturing-for-Ii-Key-SARS-CoV-2-Peptide- Vaccine-Against-the-COVID-19-Pandemic.html  Stock/Generex- https://www.fool.com/investing/2020/05/17/is- buying-a-basket-loaded-with-every-coronavirus-v.aspx “BIO, the biggest trade group representing the biotechnology industry, currently lists 28 companies that are actively involved in developing COVID-19 vaccines. Here are the 21 of those drugmakers that are publicly traded:”
  • 12.
    VAXART  SOUTH SANFRANCISCO, Calif., May 20, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”) (NASDAQ: VXRT), a clinical- stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has selected its lead COVID-19 vaccine candidate and has contracted with KindredBio to manufacture bulk vaccine under cGMP to complement the manufacturing capacity of partner Emergent BioSolutions https://www.globenewswire.com/news- release/2020/05/20/2036357/0/en/Vaxart-Announces-Selection-of- its-Oral-COVID-19-Vaccine-Lead-Candidate.html  Funding issues - https://seekingalpha.com/article/4334623-vaxarts- coronavirus-stock-bump-is-unlikely-to-continue-exit-now-be-long  Cash on hand - https://www.fool.com/investing/2020/04/28/why- vaxart-stock-slumped-today.aspx  Partnerships - https://observer.com/2020/05/covid-19-vaccine- moderna-results-new-progress/
  • 13.
    MEDICAGO  Quebec Funding- https://www.canadianmanufacturing.com/research-and- development/government-of-quebec-providing-7m-to- medicagos-covid-19-vaccine-development-249412/  Animal Trials - https://www.sttinfo.fi/tiedote/medicago- announces-positive-results-in-animal-trials-for-its-vaccine- candidate-against-covid- 19?publisherId=58763726&releaseId=69881188  Collaborative project of more than $1.2 million using artificial intelligence to optimize the production of vaccines, announced by CQDM and Medicago R&D - https://www.newswire.ca/news- releases/collaborative-project-of-more-than-1-2-million-using- artificial-intelligence-to-optimize-the-production-of-vaccines- announced-by-cqdm-and-medicago-r-amp-d-859733879.html
  • 14.
    TAKIS  “TAKIS SRLis located in ROMA, ROMA, Italy and is part of the Scientific Research & Development Services Industry. TAKIS SRL has 15 employees at this location and generates $1.78 million in sales (USD). There are 4 companies in the TAKIS SRL corporate family. https://www.dnb.com/business-directory/company- profiles.takis_srl.1084976c4f88cf6ddd4089044968c511.html  Startup - https://www.forbes.com/sites/giacomotognini/2020/04/21/inside -the-tiny-italian-biotech-startup-racing-to-develop-a- coronavirus-vaccine/#b686e172c106  Funding - https://finance.yahoo.com/news/applied-dna-takis- biotech-announce-070000273.html
  • 15.
    UPDATE – VACCINES / DEVELOPMENT Source- “” https://www.healthline.com/healt h-news/heres-exactly-where- were-at-with-vaccines-and- treatments-for-covid-19
  • 16.
    VACCINES DEVELOPMENT  GSK- https://indianexpress.com/article/coronavirus/coronavirus-covid-19-vaccine-glaxosmithkline-oxford- astrazeneca-moderna-clover-status-check-6469474/  Vaccine Tracker - https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html  Gavi organization funding from sources like Bill Gates and world governments - https://www.biopharma- reporter.com/Article/2020/06/17/Gavi-receives-billions-in-funding  Gates and Inovio - https://www.newsbreak.com/missouri/kansas-city/news/0OfXdfSR/a-potential-coronavirus- vaccine-funded-by-bill-gates-is-set-to-begin-testing-in-people-with-the-first-patient-expected-to-get-it- today
  • 17.
    ALTIMUNE  “Shares ofAltimmune (ALT) - Get Report soared Thursday after the clinical-stage biopharmaceutical company announced the next step in development of its coronavirus vaccine AdCovid. “In collaboration with the University of Alabama at Birmingham, we have commenced preclinical testing of candidates for our Covid- 19 vaccine, AdCovid,” the company said in a statement. https://www.thestreet.com/investing/altimmune-coronavirus- vaccine-preclinical-trial  Former Pfizer board director appointed to Altimmune - https://www.reuters.com/companies/ALT.OQ
  • 18.
    TESTING  COVID19 –Testing “It uses a simple assay containing plasmonic gold nanoparticles to detect a color change when the virus is present. The test does not require the use of any advanced laboratory techniques, such as those commonly used to amplify DNA, for analysis. The authors published their work last week in the American Chemical Society’s nanotechnology journal ACS Nano. "Based on our preliminary results, we believe this promising new test may detect RNA material from the virus as early as the first day of infection. Additional studies are needed, however, to confirm whether this is indeed the case,” said study leader Dipanjan Pan, PhD, professor of diagnostic radiology and nuclear medicine and pediatrics at UMSOM.” https://www.umaryland.edu/news/archived-news/may-2020/covid-19- results-in-10-minutes-umb-studies-rapid-test.php or https://www.nextbigfuture.com/2020/05/ten-minute-covid-19- detection-test-using- nanoparticles.html?utm_source=feedburner&utm_medium=feed&utm_ campaign=Feed%3A+blogspot%2Fadvancednano+%28nextbigfuture% 29
  • 19.
    TESTING KITS Source -https://www.medtechdive.com/news/coronavirus-tests-home-collection-quest-diagnostics- letsgetchecked/578837/ The cost is $129 per kit!
  • 20.
    GLOBAL MARKET /TESTING Source - https://www.globenewswire.com/news-release/2020/06/01/2041269/0/en/Global-COVID-19-diagnostic-testing-market-to-amass-USD-44481-8-million-in-2020.html • Additional costs to already strapped healthcare system • Private insurance companies and their coverage in terms of their testing. This could mean a rise in premiums • Consumers could be out of pocket about $129 per test.
  • 21.
  • 22.
    ANTIBODIES  “Much remainsto be learnt about the immunological responses to SARS-CoV-2. Nevertheless, it is becoming clear that antibodies taken from the blood serum of people who have recovered from COVID-19 can be used for treatment by being transfused into other people who have the disease”Source - https://www.nature.com/articles/d41586-020-01816-5  Disappearance of antibodies 2-3 months - https://www.medscape.com/viewarticle/932671  “Those who did not have a bad case of COVID-19 lose antibodies faster. Forty percent of asymptomatic individuals became seronegative and 12.9% of the symptomatic group became negative for IgG in the early convalescent phase. In addition, asymptomatic individuals exhibited lower levels of 18 pro- and anti-inflammatory cytokines. These data suggest that asymptomatic individuals had a weaker immune response to SARS- CoV-2 infection.mThe research, published in Nature Medicine on June 18, highlights the risks of using COVID-19 ‘immunity passports’ and supports the prolonged use of public health interventions such as social distancing and isolating high-risk groups This seems to indicate that our better bet is t-cell-related therapies and vaccines and hygiene and social distancing.  Avoid getting together with larger groups  Stay 6-10 ten feet apart if at all possible  clean your hands every hour  Source - https://www.nextbigfuture.com/2020/06/coronavirus-antibody-immunity-fades-by-70-within-2-3- months.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+blogspot%2Fadvancednano+%28nextbigfuture%29
  • 23.
    GENE RESEARCH  Genomesequencing - https://globalnews.ca/news/7072424/alberta-researchers-genome-sequence-covid-19/  AI and Genome sequencing - http://www.genomequebec.com/486-en/news-covid-19-unprecedented- research-combining-genomics-and-artificial-intelligenceicial-intelligence/  Blood type and genome - https://directorsblog.nih.gov/2020/06/18/genes-blood-type-tied-to-covid-19-risk- of-severe-disease/
  • 24.
    MITIGATION  Shutting downan economy should be last resort  Private sector is driven by cash flow.  The focus should be on infrastructure, getting goods to market, supply chain, advance technology and reforming of government - https://www.slideshare.net/paulyoungcga/canada-gdp-and-economy-truth-and-what-needs-to-change  All levels of government should review their pandemic responses to ensure they have updated their playbook  Annual audits of risk and crisis management should be completed each year - https://www.slideshare.net/paulyoungcga/the-role-of-operational-and- performancebased-auditing-on-government-and-the-private-sector  WHO needs to provide reports on virus threats including what needs to be done to mitigate the spread  https://www.slideshare.net/paulyoungcga/crisis-management-how-best-to-managed-a-crisis  More coordination by the WHO with all government including monthly status calls around threats  Reporting should also be provided on the threats including performance audits of various WHO programs  Mitigating the spread is to ensure healthcare is provided with the necessary equipment - https://www.cdc.gov/coronavirus/2019-ncov/hcp/ppe-strategy/index.html  Sterilization methods of equipment and masks - https://www.inthehammer.com/hamilton-firms-technology-addresses-covid- waste-and-ppe-shortage  Protecting the most vulnerable  Screening at hospitals and long-term care facilities  Restricting the movement of staff between facilities
  • 25.
    UPDATE – JUNE23, 2020 TO JULY 1, 2O20  State of affairs with COVID19 - https://www.healthline.com/health-news/heres-exactly-where-were-at-with-vaccines- and-treatments-for-covid-19  Line is forming for the vaccine - https://www.sciencemag.org/news/2020/06/line-forming-covid-19-vaccine-who- should-be-front  You cannot shut down the economy, but all levels of government including the private sector need to take mitigating steps - https://www.slideshare.net/paulyoungcga/transforming-the-economy-postcovid19-canada-and-the-world  China is using the pandemic to make changes with laws for Hong Kong - https://www.cnn.com/2020/07/01/asia/hong-kong-national-security-law-intl-hnk/index.html  USA buys up key drug - https://globalnews.ca/news/7127951/us-remdesivir-supply-coronavirus/  Antibody treatment - https://www.cnn.com/2020/06/26/health/antibody-therapies-covid-19-update- wellness/index.html
  • 26.
    VACCINES, HEALTH ANDSAFETY AND TESTING UPDATE  USA clinical trials - https://globalnews.ca/news/7178006/us-coronavirus-vaccine-testing/  Human trials in Quebec - https://www.cbc.ca/news/health/human-trials-covid-19-vaccine-candidate-quebec- 1.5648648  World and treatment of COVID19 - https://www.healthline.com/health-news/heres-exactly-where-were-at-with- vaccines-and-treatments-for-covid-19#Antivirals  Vaccines Trials - https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html  Mobile testing kits - https://www.thestar.com/business/2020/07/09/guelph-companys-mobile-covid-19-test-kit-hits- market-and-heads-for-norther-ontario.html  Workplace measures - https://www.ontario.ca/page/develop-your-covid-19-workplace-safety-plan or http://www.worksafesask.ca/covid-19/conducting-a-hazard-assessment-and-developing-a-safety-plan/  Mobile workers - https://www.carsondesign.com/2017/12/designing-your-office-space-for-the-mobile-workforce/
  • 27.
    TRAINING AND DEVELOPMENT If you like to learn more about trade and/or other subjects as part of your professional learning and development then feel free to review my material on https://www.udemy.com/ (search Paul Young CPA CGA)  These subjects address how to fixed issues with housing and/or systemic issues related to economy including government policies
  • 28.
    SUMMARY  There aremany companies involved with research and development of COVID19 vaccine - https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=677  Bill and Melinda Gates Foundation are playing a key role with funding and manufacturing - https://www.geekwire.com/2020/gates-foundation-commits-50m- covid-19-vaccine-initiative-total-funding-now-tops-300m/ (Funding is now over $300M (USD)  There are allot of startups involved. Various Canadian governments have been funding VC companies related to biotech research  There appears to be lack of progress reports on the state of affairs when it comes to government money going to vaccinations R&D - https://cmajnews.com/2020/05/20/coronavirus-1095847/  There is allot of speculator investments going on with biotech companies as part of reaping the rewards when vaccines go to market.  Major pharma continues to work with government, institution, labs, Tech, etc. https://www.bioworld.com/articles/435263-astrazeneca-moving-at-warp-speed-with- 12b-in-barda-funding-for-covid-19-vaccine  Economy could see periods of slow growth for years - https://www.slideshare.net/paulyoungcga/transforming-the-economy-postcovid19- canada-and-the-world or https://www.investmentexecutive.com/news/research-and- markets/covid-19-to-reshape-economy-society-moodys/

Editor's Notes

  • #6 Source - https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker
  • #7 Moderna - https://investors.modernatx.com/financial-information/sec-filings and https://finance.yahoo.com/quote/MRNA/key-statistics/
  • #22 Source - https://www.theepochtimes.com/hydroxychloroquine-study-corrected-after-more-than-100-scientists-question-findings_3371001.html or https://www.marketwatch.com/press-release/hydroxychloroquine-market-2020-global-trends-growth-size-opportunities-regional-overview-leading-company-analysis-and-key-country-forecast-to-2026-2020-06-01?tesla=y or https://www.newindianexpress.com/states/karnataka/2020/apr/08/pharma-firms-await-ingredient-from-china-to-make-sought-after-drug-hcq-2127181.html